Generating AI analysis...
Revenue
$14.88B
-19.51% YoY
EPS (Basic)
$0.55
-43.88% YoY
Evidence Layer
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue | $14.88B | $18.49B | -19.51% |
Cost of Revenue | $3.38B | $4.89B | -30.84% |
Net Income | $3.12B | $5.54B | -43.80% |
EPS (Basic) | $0.55 | $0.98 | -43.88% |
EPS (Diluted) | $0.55 | $0.97 | -43.30% |
SG&A Expense | $3.5B | $3.42B | +2.25% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Total Assets | $221.09B | $195.62B | +13.02% |
Current Assets | $42.41B | $50.08B | -15.30% |
Total Liabilities | $128.54B | $94.38B | +36.19% |
Current Liabilities | $40.5B | $36.56B | +10.76% |
Stockholders' Equity | $92.28B | $100.97B | -8.60% |
Cash & Equivalents | $719M | $2.17B | -66.81% |
Long-Term Debt | $61.31B | $31.7B | +93.37% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Cash Flow | $1.09B | $1.21B | -10.07% |
Investing Cash Flow | $1.73B | $3.31B | -47.75% |
Financing Cash Flow | $-4.93B | $-2.77B | -77.95% |
D&A | $1.74B | $1.49B | +16.75% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Net Margin | 20.9% | — | — |
ROE | 3.4% | — | — |
ROA | 1.4% | — | — |
Current Ratio | $1.047 | — | — |
Debt to Equity | $1.393 | — | — |
Other companies in Pharmaceuticals